Bone marrow hemodilution assessment in multiple myeloma MRD by next generation flow cytometry - a mini review
Bone marrow hemodilution could compromise next generation flow cytometry based measurable residual disease evaluation in multiple myeloma and may cause false negative results. This review summarizes definitions, markers, indices, mitigation strategies, and current challenges in standardization.
Authors
- Sorina Bădeliță (ORCID: https://orcid.org/0000-0002-1507-2547)
- Daniel Coriu (ORCID: https://orcid.org/0000-0002-7251-6079)
- Horia Mihail Sandu (ORCID: https://orcid.org/0009-0004-7987-9106)
- Delia Codruţa Popa (ORCID: https://orcid.org/0000-0002-7638-3285)
Institutions
- Carol Davila University of Medicine and Pharmacy (RO)
- Avila University (US)
- Institutul Clinic Fundeni (RO)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-05-01
- DOI
- https://doi.org/10.3389/fonc.2026.1849714
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00